Stock NNG NANOGROUP S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials NanoGroup S.A.

Equities

NNG

PLNNGRP00011

Biotechnology & Medical Research

Market Closed - Warsaw S.E.
Other stock markets
 09:25:50 26/04/2024 pm IST 		5-day change 1st Jan Change
1.02 PLN -0.49% Intraday chart for NanoGroup S.A. -0.97% +9.91%
2023 NanoGroup S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
2023 NanoGroup S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 41.5 31.65 20.66 73.36 60.12 20.83
Enterprise Value (EV) 1 36 27.15 19.28 63.47 56.41 20.83
P/E ratio -20.6 x -13.5 x -13.4 x -14.1 x -6.01 x -24.8 x
Yield - - - - - -
Capitalization / Revenue 157 x 102 x 39.9 x 107 x 122 x 149 x
EV / Revenue 137 x 87.4 x 37.2 x 92.3 x 115 x 149 x
EV / EBITDA -18.4 x -11.6 x -11.6 x -19.8 x -18.7 x 43.7 x
EV / FCF -2.96 x -3.05 x -5.02 x -15.7 x -28.1 x -
FCF Yield -33.7% -32.8% -19.9% -6.35% -3.55% -
Price to Book 3.24 x 2.23 x 1.68 x 4.16 x 7.77 x -
Nbr of stocks (in thousands) 12,970 12,970 13,957 16,748 16,748 16,748
Reference price 2 3.200 2.440 1.480 4.380 3.590 1.244
Announcement Date 02/05/18 03/05/19 29/05/20 30/04/21 04/05/22 28/04/23
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.2635 0.3108 0.5177 0.6875 0.4925 0.1395
EBITDA 1 -1.961 -2.35 -1.661 -3.207 -3.023 0.4772
EBIT 1 -2.015 -2.405 -1.709 -3.264 -3.074 0.415
Operating Margin -764.56% -773.94% -330.12% -474.76% -624.12% 297.4%
Earnings before Tax (EBT) 1 -2.035 -2.423 -1.538 -5.244 -10.69 -0.7835
Net income 1 -2.013 -2.345 -1.536 -5.189 -10.01 -0.8386
Net margin -764.01% -754.37% -296.71% -754.79% -2,031.6% -600.93%
EPS 2 -0.1552 -0.1808 -0.1101 -0.3098 -0.5974 -0.0501
Free Cash Flow 1 -12.15 -8.913 -3.841 -4.032 -2.004 -
FCF margin -4,610.21% -2,867.74% -741.9% -586.43% -406.98% -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 02/05/18 03/05/19 29/05/20 30/04/21 04/05/22 28/04/23
1PLN in Million2PLN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 5.51 4.49 1.37 9.88 3.71 -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -12.1 -8.91 -3.84 -4.03 -2 -
ROE (net income / shareholders' equity) -15.1% -16.3% -11.3% -33.1% -78.7% -12.1%
ROA (Net income/ Total Assets) -5.99% -6.06% -4.09% -7.23% -7.63% -
Assets 1 33.62 38.71 37.55 71.75 131.1 -
Book Value Per Share 2 0.9900 1.100 0.8800 1.050 0.4600 -
Cash Flow per Share 2 0.4300 0.3500 0.1400 0.6200 0.2400 -
Capex 1 5.82 0.06 0.04 0.15 0.05 0.01
Capex / Sales 2,206.83% 18.03% 7.01% 21.43% 10.16% 6.03%
Announcement Date 02/05/18 03/05/19 29/05/20 30/04/21 04/05/22 28/04/23
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NANOGROUP S.A. Stock NanoGroup S.A.
+9.91% 5.06M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NNG Stock
  4. Financials NanoGroup S.A.